10:12:36 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-27 X-dag ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 Årsstämma 2024
2024-06-24 Kvartalsrapport 2024-Q1
2024-03-27 Extra Bolagsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 X-dag ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 X-dag ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 X-dag ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 X-dag ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50


ListaEuronext Growth Oslo
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2024-04-15 08:30:00
Not for release, publication or distribution, in whole or in part directly or
indirectly, in Australia, Canada, Japan or the United States (or any other
jurisdiction in which the release, publication or distribution would be
unlawful). This announcement does not constitute an offer of any of the
securities described herein.

Oslo, Norway, 15 April 2024: Reference is made to the previous stock exchange
announcements from SoftOx Solutions AS (the "Company") regarding the completion
of the private placement and the contemplated subsequent offering (the
"Subsequent Offering") as described therein.

The subscription period in the Subsequent Offering commences today, Monday 15
April 2024 at 09:00 hours (CEST) and will end on 29 April 2024 at 16:30 hours
(CEST) (the "Subscription Period").

The Subsequent Offering consists of an offering of up to 125,000,000 shares (the
"Offer Shares") in the Company at a subscription price of NOK 0.2 per Offer
Share. The Subsequent Offering is directed towards existing shareholders in the
Company as of March 27 2024, as registered in the Company's shareholder register
at Euronext Securities Oslo (VPS) on 3 April 2024 ("Record Date"), and who (i)
were not included in the pre-sounding phase of the private placement, (ii) were
not allocated offer shares in the private placement, and (iii) are not resident
in a jurisdiction where such an offer would be illegal or would (in
jurisdictions other than Norway) require a prospectus, filing, registration, or
similar action (the "Eligible Shareholders")

Each Eligible Shareholder will receive 12.644 non-tradeable subscription rights
(the "Subscription Rights") for each share held by such Eligible Shareholder in
the Company as of the Record Date. Each Subscription Right gives, subject to
certain limitations based on applicable laws and regulations, the right to
subscribe for, and be allocated one (1) Offer Share in the Subsequent Offering
at the Offer Price. The number of Subscription Rights granted to each Eligible
Shareholder will be rounded down to the nearest whole Subscription Right.
Over-subscription is allowed. Subscription without Subscription Rights is not

In order to subscribe for Offer Shares, you must either send in a complete and
duly signed subscription form to the Manager (as defined below) or subscribe
thought VPS online subscription system available for Norwegian citizens, within
the end of the Subscription Period. Further instructions regarding the
subscription procedure are available in the Prospectus that has been registered
with the Norwegian Register of Business Enterprises.

Subscription Rights that are not exercised before 16.30 CEST on 29 April 2024
will have no value and will lapse without compensation to the holder.

The due date for payment of the Offer Shares is 2 May 2024. The Offer Shares
will, after registration of the share capital increase in the Norwegian Register
of Business Enterprises pertaining to the Offer Shares, be registered in the VPS
in book-entry form and are expected to be delivered to the applicant's VPS
account on or about 10 May 2024. The Offer Shares will have equal rights and
rank pari passu with the Company's other shares.

Please see the Prospectus for more information about the Subsequent Offering.
The Prospectus, including a subscription form, is made electronically available
at www.soft-ox.com and www.sb1markets.no.

Sparebank 1 Markets ("Manager") is acting as Manager in the Subsequent Offering.
Kvale Advokatfirma acts as legal advisor in the Subsequent Offering,

For any questions or interview requests, please contact:
Geir Almås, Chair of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Geir Almås: (+47) 977 59 071
About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com